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Site-directed mutagenesis of HIV-1 vpu gene demonstrates 
two clusters of replication-defective mutants with distinct 
ability to down-modulate cell surface CD4 and tetherin
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HIV-1 Vpu acts positively on viral infectivity by mediating CD4 degradation in endoplasmic 
reticulum and enhances virion release by counteracting a virion release restriction factor, tetherin. 
In order to define the impact of Vpu activity on HIV-1 replication, we have generated a series of 
site-specific proviral vpu mutants. Of fifteen mutants examined, seven exhibited a replication-
defect similar to that of a vpu-deletion mutant in a lymphocyte cell line H9. These mutations 
clustered in narrow regions within transmembrane domain (TMD) and cytoplasmic domain 
(CTD). Replication-defective mutants displayed the reduced ability to enhance virion release 
from a monolayer cell line HEp2 without exception. Upon transfection with Vpu expression 
vectors, neither TMD mutants nor CTD mutants blocked CD4 expression at the cell surface 
in another monolayer cell line MAGI. While TMD mutants were unable to down-modulate cell 
surface tetherin in HEp2 cells, CTD mutants did quite efficiently. Confocal microscopy analysis 
revealed the difference of intracellular localization between TMD and CTD mutants. In total, 
replication capability of HIV-1 carrying vpu mutations correlates well with the ability of Vpu to 
enhance virion release and to impede the cell surface expression of CD4 but not with the ability 
to down-modulate cell surface tetherin. Our results here suggest that efficient viral replication 
requires not only down-regulation of cell surface tetherin but also its degradation.
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Mitchell et al., 2009). Vpu appears to direct tetherin to trans-Golgi 
network (TGN) or to early endosomes for β-TrCP dependent pro-
teasomal or lysosomal degradation (Douglas et al., 2009; Goffinet 
et al., 2009; Iwabu et al., 2009; Mangeat et al., 2009). Since binding 
of Vpu to tetherin partially relieves the restriction of virion release 
by tetherin, depletion of total cellular tetherin does not entirely 
account for counteraction of Vpu (Mangeat et al., 2009; Dubé et al., 
2010). It also has been shown that Vpu enhances virion release even 
in the absence of down-modulation of cell surface and intracellular 
tetherin (Miyagi et al., 2009). The exact mechanism for antagonism 
of tetherin by Vpu remains to be elucidated. Early work proposed 
that two separable biological activities are directed by distinct Vpu 
domains: TMD is important for virion release enhancement and 
CTD, especially serine 52 and 56, is critical for CD4 degradation 
(Schubert and Strebel, 1994; Schubert et al., 1996). Recent studies 
have suggested that both TMD and CTD are involved in two major 
functions of Vpu (Van Damme et al., 2008; Douglas et al., 2009; 
Mangeat et al., 2009; Magadán et al., 2010). Functional domains of 
Vpu and mechanism by which Vpu mediates CD4 degradation and 
counteracts tetherin have been intensively studied using mainly a 
randomized mutants of TMD and serine 52 and/or 56 mutants in 
CTD. However, functional mapping of Vpu and its effect on HIV-1 
replication have not been well studied.
In this study, to better define HIV-1 Vpu functions for viral rep-
lication, we performed a comprehensive and systemic analysis using 
a series of site-specific vpu mutants. Virological analysis of the vpu 
IntroductIon
Accessory protein Vpu is encoded only by HIV-1 and certain strains 
of simian immunodeficiency virus (Desrosiers, 2007; Kirchhoff, 
2009). HIV-1 Vpu is a phosphorylated type I integral membrane 
protein and consists of two major domains, that is, an N-terminal 
transmembrane domain (TMD) and a cytoplasmic domain (CTD) 
(for review, Nomaguchi et al., 2008). Major functions of HIV-1 Vpu 
are: (1) to give a positive effect on viral infectivity by mediating 
CD4 degradation in endoplasmic reticulum (ER) (Bour and Strebel, 
2003; Levesque et al., 2003; Tanaka et al., 2003), and (2) to enhance 
virion release in a cell-type dependent manner by counteracting 
a host restriction factor, tetherin (Strebel et al., 1989; Terwilliger 
et al., 1989; Sakai et al., 1995; Neil et al., 2008; Van Damme et al., 
2008). For CD4 degradation, Vpu binds to newly synthesized CD4 
in ER and recruits β-TrCP, which is a component of E3 ubiquitin 
ligase complex, via two conserved serine residues (at positions 52 
and 56). Subsequently, CD4 is ubiquitinated and degraded by 26S 
proteasomes (Lenburg and Landau, 1993; Bour et al., 1995; Paul and 
Jabbar, 1997; Margottin et al., 1998). For virion release enhance-
ment, Vpu counteracts tetherin that is induced by type I interferon 
(Neil et al., 2007, 2008; Van Damme et al., 2008). Tetherin traps 
nascent virions at cell surface and restricts virion release of vari-
ous viruses including retroviruses, arenaviruses, filoviruses, and 
herpesviruses (for review, Tokarev et al., 2009; Douglas et al., 2010; 
Sauter et al., 2010). Vpu down-modulates cell surface tetherin and 
modestly decreases total cellular tetherin (Van Damme et al., 2008; 
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equivalent amounts (5 × 106 cpm) of various viruses as determined 
by reverse transcriptase (RT) assays, and monitored for virus repli-
cation by RT assays as previously described (Willey et al., 1988).
AssAys for vIrIon releAse from cells
HEp2 cells were transfected with proviral clones by CPC followed 
by glycerol treatment (20% glycerol in MEM without FBS). On day 
2 post-transfection, culture supernatants were collected and virions 
released from cells were determined by RT assays. Virion release 
assays in 293T cells were similarly performed; no glycerol treat-
ment following CPC transfection. For analysis of Vpu expression 
vectors, subconfluent HEp2 cells in 24 well-dishes were transfected 
with 300 ng of pNL-uE65, 200 ng of pSG5, and 200 ng of pIRES-
hrGFP-Vpu vectors or pSG-VpucFLAG vectors by Lipofectamine 
2000 (Invitrogen, Carlsbad, USA). At 6 h post-transfection, culture 
medium was replaced with fresh 10% FBS-MEM and cells were 
incubated for 2 days. Viral production in the culture supernatants 
was determined by RT assays.
Western blot AnAlysIs
For analysis of Vpu expression by proviral clones, transfected HEp2 
cells were lysed with CHAPS buffer (10 mM CHAPS, 150 mM NaCl, 




, and 10 mM Na-phosphate pH 7.4). 
For analysis of Vpu expression by subgenomic vectors, transfected 
293T cells were lysed in TNE buffer (10 mM Tris–HCl pH 8.0, 
1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, and 1% protease 
inhibitor cocktail (SIGMA-ALDRICH)]. Vpu in cell lysates were 
monitored as previously described (Yamashita et al., 2008) using 
anti-FLAG (SIGMA-ALDRICH), anti-β actin (SIGMA-ALDRICH), 
anti-p24 (NIH AIDS Research and References Reagent Program), 
or anti-Vpu (NIH AIDS Research and References Reagent 
Program) antibody.
floW cytometry AnAlysIs
For analysis of cell surface CD4, MAGI cells in 60 mm dishes were 
transfected with 5 μg of pIRES-hrGFP-Vpu vectors by CPC. On 
day 2 post-transfection, cells were trypsinized, washed with PBS, 
and resuspended in FACS washing buffer (10% FBS in PBS). Cells 
were then stained with a PE conjugate mouse anti-human CD4 
antibody (BD Biosciences, San Jose, USA). For analysis of cell sur-
face tetherin, HEp2 cells in 60 mm dishes were transfected with 
pIRES-hrGFP-Vpu vectors and harvested as described above. Cells 
were then stained with an anti-HM1.24 monoclonal antibody (a 
generous gift from Chugai Pharmaceutical Co., Tokyo, Japan) and a 
secondary PE conjugate anti-mouse Ig antibody (BD Biosciences). 
Stained cells were analyzed by FACSCalibur and CELLQuest 
 software (BD Biosciences).
confocAl mIcroscopy
HEp2 cells were seeded onto 4-well Lab-Tek chambered coverglasses 
(Nalge Nunc International, Rochester, USA), incubated overnight, 
and transfected with a pNL-uE65 (300 ng), pSG-VpucFLAG vectors 
(200 ng), and pSG5 (200 ng) by Lipofectamine 2000 (Invitrogen). 
On the next day, cells were fixed with 4% paraformaldehyde, per-
meabilized with 0.2% Triton X-100, and incubated with a first 
antibody [anti-TGN46 (Novus Biologicals, Inc., Littleton, USA), 
anti-FLAG, or anti-HM1.24 antibody]. Cells were then incubated 
mutants in a lymphocyte cell line identified two clusters in TMD and 
CTD important for efficient viral replication. Vpu mutants within 
these two clusters exhibited the reduced ability to enhance virion 
release and to disturb CD4 expression at the cell surface. While CTD 
mutants extensively colocalized with tetherin in intracellular compart-
ments and exhibited the capability to down-modulate cell surface 
tetherin, TMD mutants failed to do so. In sum, our results show that 
replication capability of the vpu mutations correlates with ability to 
augment virion release and to down-modulate CD4 but not to down-
regulate cell surface tetherin. This finding suggests that antagonism of 
tetherin by Vpu for optimal viral replication may require tetherin deg-
radation in addition to down-modulation of cell surface tetherin.
mAterIAls And methods
plAsmId dnA
Construction of a series of site-specific HIV-1 vpu mutants from 
pNL4-3 (Adachi et al., 1986) was carried out by the QuickChange 
site-directed mutagenesis kit (Stratagene, La Jolla, USA). Amino 
acid and nucleotide substitutions are as follows: V9D and V13D (gta 
to gac), I19D and I24D (ata to gac), RK30AA (agg aaa to gcg gca), 
Q35A (caa to gca), D43A (gat to gct), E47A (gaa to gca), EDS50AAA 
(gaa gac agt to gca gca gct), S52A (agt to gct), S56G (agt to ggt), E59K 
(gaa to aaa), M66V and M70V (atg to gtg), and P75S (cct to tct). A 
vpu-deletion mutant, pNL-uE65 (Iida et al., 1999), was generated by 
replacing the initiation codon (ATG) to AGG. For flow cytometry 
analysis, vectors co-expressing Vpu by cytomegalovirus promoter 
(CMV P) and GFP via an internal ribosomal entry site (IRES) were 
constructed as follows. Wild-type (WT) and mutated vpu sequences 
were amplified by PCR using forward primer (Vpu-5-SacII: 
TCCCCGCGGATGCAACCTATAATAGTAGC), reverse primer (U 
down BamHI: CGCGGATCCCTACAGATCATCAATATCCC), and 
pNL4-3 derived sequences as template. Amplified products were then 
digested with SacII and BamHI, cloned into pIRES-hrGFP-1a vector 
(Stratagene), and resultant clones were designated pIRES-hrGFP-
Vpu vectors. To analyze intracellular localization of Vpu, vectors 
expressing C-terminally FLAG-tagged Vpu were generated. Vpu 
genes were amplified by PCR using forward primer (EcoRI-5-Vpu: 
CGGAATTCAAGGATGCAACCTATAATAGTAGC), reverse primer 
(Vpu-3-XhoI: CCGCTCGAGCAGATCATCAATATCCCAAG), and 
proviral vpu mutant clones as template, and cloned into pSG-
cFLAG as described previously (Wang et al., 2005). The resultant 
clones were designated pSG-VpucFLAG vectors.
cells
293T (Lebkowski et al., 1985) and HEp2 cells (ATCC CCL-23) were 
maintained in Eagle’s minimal essential medium (MEM) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS). MAGI 
cells (Kimpton and Emerman, 1992) were cultured in MEM con-
taining 10% FBS, 200 μg/mL G418 (SIGMA-ALDRICH, St. Louis, 
USA), and 100 μg/mL hygromycin B (SIGMA-ALDRICH). H9 cells 
(Mann et al., 1989) were maintained in RPMI1640 medium sup-
plemented with 10% FBS.
AssAys for vIrAl replIcAtIon
Input viruses were prepared from 293T cells transfected with pro-
viral clones by the calcium-phosphate co-precipitation method 
(CPC; Adachi et al., 1986). H9 cells (1 × 106) were infected with 
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Asp43, Glu47, GluAspSer50, and Ser52) were generated by Ala-
substitution, and the other mutants (Ser56, Glu59, Met66, Met70, 
and Pro75) contained amino acids with physicochemical property 
distinct from authentic ones (Gly, Lys, Val, Val, and Ser, respec-
tively). Since Ser52 and Ser56 are key residues to interact with 
β-TrCP (Schubert and Strebel, 1994; Margottin et al., 1998), it 
is expected that S52A and S56G mutations disrupt the ability to 
recruit E3 ubiquitin ligase complex and the following degrada-
tion of target proteins.
To determine replication kinetics, mutant virus stocks were 
prepared from transfected 293T cells and inoculated into a Vpu-
dependent lymphocyte cell line H9 (Figures 1B–E). Out of fifteen 
mutants shown in Figure 1A, seven (V9D, V13D, I19D, EDS50AAA, 
S52A, S56G, and E59K) exhibited a replication-defect similar to that 
of a vpu-deletion mutant (∆Vpu in Figures 1B–E) in H9 cells. The 
other mutant viruses were found to have a replication potential 
similar to that of WT virus. Viral clone carrying I24D mutation 
had a small replication-defect but appeared not to be significant 
(Figure 1E). In total, the results described above demonstrate that 
narrow regions in Vpu TMD and CTD are required for efficient 
viral replication.
replIcAtIon-defectIve vpu mutAnts dIsplAy reduced AbIlIty to 
enhAnce vIrIon releAse In hep2 cells
It has been shown previously that Vpu is required to promote 
virion release in tetherin-positive cells (e.g., HeLa, HEp2, T cells, 
and macrophages) but dispensable in tetherin-negative cells (e.g., 
293T, HT1080, and COS-7; Sakai et al., 1995; Neil et al., 2008). To 
determine if mutations in vpu affect progeny production, proviral 
mutant clones were transfected into HEp2 and 293T cells, and 
virion level in the culture supernatants was determined by RT 
assays. In HEp2 cells, control ∆Vpu and seven TMD (V9D, V13D, 
and I19D) and CTD (EDS50AAA, S52A, S56G, and E59K) mutants 
exhibited two- to three-fold reduction of virus production relative 
to WT (Figure 2A). These seven mutants were replication-defective 
in H9 cells (Figures 1B–E). The other eight mutants behaved simi-
larly with WT with respect to virion production in HEp2 cells. As 
expected, all mutant clones were indistinguishable from WT in 
293T cells (Figure 2B). Vpu expression level in HEp2 cells was 
different among proviral clones in this particular experiment 
(Figure 2C), but virion level was not correlated to the amount of 
Vpu (Figures 2A–C). The results described above indicate that, in 
the presence of tetherin, efficient viral replication coincidentally 
occurred with promotion of virion release by Vpu.
replIcAtIon-defectIve tmd (v9d And I19d) And ctd (s56G And 
e59K) mutAnts lAcK the AbIlIty to doWn-modulAte cd4
Down-modulation of CD4 appears to be important for HIV-1 
replication, since numbers of viral proteins (Env, Nef, and Vpu) 
show this particular activity. For analysis of CD4 and tetherin 
down-regulation by Vpu, we generated constructs that co-express 
Vpu (target for study) and GFP (transfection marker). To confirm 
the activity of these constructs, Vpu expression and virion pro-
duction level were examined. As shown in Figure 3, these vectors 
expressed the Vpu proteins and complemented virion production 
of ∆Vpu to a similar extent with that observed in the provirus 
experiment (Figure 2A).
with an appropriate secondary antibody [Alexa Fluor 488 or 555 
SFX kit (Invitrogen)] according to manufacturer’s instructions, 
and cell nuclei were counterstained with DAPI. Cell images were 
obtained by DIGITAL ECLIPSE C1si-Ready (Nikon Co., Tokyo, 
Japan) and analyzed by EZ-C1 viewer (Nikon Co.).
results
AmIno AcIds In vpu ImportAnt for effIcIent hIv-1 replIcAtIon 
Are clustered In nArroW reGIons WIthIn tmd And ctd
HIV-1 Vpu has been shown to positively modulate viral infectiv-
ity by mediating CD4 degradation and also to promote virion 
release by down-modulating tetherin (Levesque et al., 2003; Neil 
et al., 2008; Van Damme et al., 2008). The correlation between 
the viral replication and the two Vpu functions has been exam-
ined for a limited number and kind of vpu mutants (Terwilliger 
et al., 1989; Schubert et al., 1996; Van Damme et al., 2008; Dubé 
et al., 2010). To study functional role of Vpu in viral replication 
more clearly and extensively, we generated a series of proviral 
vpu mutants (Figure 1A). Substitutions were introduced into 
residues that are well-conserved among viruses of HIV-1 group 
M. For mutations within TMD, Val9, Val13, Ile19, and Ile24 were 
replaced with Asp, respectively. By these substitutions, TMD was 
changed to contain a negatively charged amino acid in place of 
non-charged amino acids. Some CTD mutants (ArgLys30, Gln35, 
FIgure 1 | HIV-1 vpu mutants used in this study. (A) Locations of 
mutations in Vpu (NL4-3 clone) and the mutant designations. Bold letters 
indicate replication-defective mutants in H9 cells. The I24D mutant displayed a 
small replication-defect in H9 cells. Colored areas show functional regions of 
Vpu involved in viral replication. (B–e) Replication kinetics of various vpu 
mutants in H9 cells. H9 cells (1 × 106) were infected with equivalent RT units 
(5 × 106) of cell-free viruses prepared from transfected 293T cells. Virus 
replication was monitored at intervals by RT production in the culture 
supernatants.
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Vpu. In addition, mutants S56G and E59K effectively reduced the 
tetherin. In contrast, some TMD mutants (V9D and I19D) did not 
decrease tetherin from cell surface. While these two TMD mutants 
did not enhance virion release as expected, CTD mutants S56G and 
E59K did so considerably (Figure 3B). In sum, TMD mutants V9D 
and I19D did not promote virion release and did not down-modulate 
cell surface tetherin. CTD mutants S56G and E59K did not enhance 
virion release but did reduce cell surface tetherin. These results show 
that, two activities of Vpu, i.e., down-modulation of cell surface teth-
erin and enhancement of virion release, are not always correlated.
the AbIlIty of vpu to colocAlIze WIth tetherIn Is pArAllel to Its 
cApAbIlIty to doWn-modulAte cell surfAce tetherIn but not 
to enhAnce vIrIon releAse
Recent studies have suggested that the ability of Vpu to localize 
to TGN and to colocalize with tetherin is important to elicit anti-
tetherin activity, and that this property of Vpu correlates with virion 
To determine whether Vpu mutant proteins down-modulate 
CD4, we evaluated its expression level at the surface of transfected 
MAGI cells (CD4-positive HeLa cells) (Figure 4). Some mutants 
(I24D, RK30AA, and M70V) were able to decrease the cell surface 
level of CD4 equally efficiently with WT Vpu. In contrast, mutants 
V9D, I19D, S56G, and E59K failed to down-modulate cell surface 
CD4. These four mutants were all replication-defective in H9 cells 
(Figure 1). Thus, viral replication potential and ability to down-
modulate CD4 by Vpu are correlated.
vpu ctd mutAnts (s56G And e59K) Are Able to doWn-modulAte 
tetherIn from the cell surfAce of hep2 cells but not tmd 
mutAnts (v9d And I19d)
Down-modulation of cell surface tetherin by Vpu has been shown to 
be important for enhancement of virion release from HeLa cells (Van 
Damme et al., 2008; Mitchell et al., 2009). It also has been reported 
that, during infection of T cell lines with viruses carrying S52 and 
S56 mutations, cell surface level of tetherin was partially reduced 
(Douglas et al., 2009) or unchanged (Miyagi et al., 2009). To assess the 
potential of mutant Vpu proteins, we analyzed cell surface tetherin on 
HEp2 cells expressing Vpu. HEp2 cells were transfected with vectors 
co-expressing Vpu and GFP as above, and monitored for expression 
level of cell surface tetherin by flow cytometry (Figure 5). Some 
mutants (I24D, RK30AA, and M70V), which promote virion release 
(Figure 3B), down-modulated cell surface tetherin as effective as WT 
FIgure 2 | Ability of proviral vpu mutants to enhance virion release from 
cells. (A,B) Cells indicated were transfected with 10 μg of proviral clones, and 
on day 2 post-transfection, culture supernatants were collected and virion 
production was determined by RT assays. Values represent virion production 
level relative to that by WT clone (NL4-3). Black and gray bars indicate WT 
(pNL4-3) and ∆Vpu (pNL-uE65) proviral constructs, respectively. Replication-
defective mutants in H9 cells are shown by blue bars. (C) Western blot 
analysis of Vpu expression in lysates of transfected HEp2 cells. Protein 
amounts loaded were 1 ng of Gag-p24. EV, empty vector control.
FIgure 3 | Trans-complementation assay for virion release from Hep2 
cells. (A) Western blot analysis of Vpu expression in lysates of 293T cells 
transfected with various pIRES-hrGFP-Vpu vectors. Equivalent amounts of 
total protein (15 μg) were loaded and Vpu was detected by anti-Vpu antibody. 
β-actin was used as a control. EV, empty vector control. (B) Virion release 
assays. HEp2 cells were transfected with the indicated proviral constructs 
(300 ng) and pIRES-hrGFP-Vpu vectors (200 ng), and virion production in the 
culture supernatants on day 2 post-transfection was determined by RT assays. 
Values represent virion production level relative to that by WT proviral clone 
(NL4-3). Gray bar shows the results of proviral ∆Vpu (NL-uE65). Black bar 
indicates the results of complementation of ∆Vpu (pNL-uE65) by WT Vpu 
(pIRES-hrGFP-WTVpu). Blue and white bars show the results of expression 
vectors derived from replication-defective and replication-normal mutants in 
H9 cells, respectively. EV, empty vector control pSG5 (400 ng).
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FIgure 4 | Ability of Vpu mutants to down-modulate cell surface CD4. 
MAGI cells were transfected with 5 μg of an empty vector, a vector encoding 
WT Vpu, or vectors encoding the indicated Vpu mutant protein and GFP as in 
Figure 3. On day 2 post-transfection, cells were strained for cell surface CD4 
and analyzed by two-color flow cytometry. Histograms represent relative cell 
number vs. CD4 fluorescence intensity for GFP-positive cells. Broken lines 
indicate the results of empty vector control, and gray shaded areas indicate the 
results of WT Vpu. Solid lines show the results of indicated mutants.
FIgure 5 | Ability of Vpu mutants to down-modulate cell surface tetherin. 
HEp2 cells were transfected with 5 μg of an empty vector, a vector encoding WT 
Vpu, or vectors encoding the indicated Vpu mutant protein and GFP as in 
Figure 3. On day 2 post-transfection, cells were strained for cell surface tetherin 
and analyzed by two-color flow cytometry. Histograms represent relative cell 
number vs. tetherin fluorescence intensity for GFP-positive cells. Broken lines 
indicate the results of empty vector control, and gray shaded areas indicate the 
results of WT Vpu. Solid lines show the results of indicated mutants.
release enhancement (Dubé et al., 2009, 2010). Therefore, we exam-
ined mutational effects of Vpu on its intracellular localization. For 
microscopic analysis, we generated vectors encoding C-terminally 
FLAG-tagged Vpu, and verified their protein expression and ability 
to promote virion production from cells. As shown in Figure 6, 
these vectors expressed the Vpu proteins and complemented virion 
production of ∆Vpu to a similar extent with that observed in the 
provirus experiment (Figure 2A).
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 cytoplasm. A portion of the mutant was noted to exist with TGN46. 
Furthermore, this mutant colocalized less extensively with tetherin. 
Another Vpu TMD mutant V9D exhibited a similar phenotype 
with the I19D mutant (data not shown). Such a clear change in 
subcellular localization of Vpu TMD mutants has not been reported 
previously (Tiganos et al., 1998; Dubé et al., 2010). A third TMD 
mutant I24D exhibited a similar intracellular distribution with 
WT Vpu. Taken together, the evident alteration of intracellular 
localization by V9D and I19D mutations may have resulted from 
introducing a negatively charged amino acid into these residues, 
and show their critical importance for function of TMD.
In contrast to TMD mutants, a CTD mutant E59K was defective 
for virion release enhancement but efficiently down-modulated cell 
surface tetherin. As expected, E59K was co-stained with TGN46. 
Interestingly, this mutant colocalized with tetherin more exten-
sively than WT Vpu. Another CTD mutant S56G also colocalized 
with tetherin extensively (data not shown). The results for localiza-
tion of our CTD mutants (S56G and E59K) were consistent with 
a previous report (Dubé et al., 2010). Extensive colocalization of 
these CTD mutants could explain efficient down-modulation of 
cell surface tetherin (Figure 5). The result for E59K also suggests 
that amino acid residue(s) close to β-TrCP binding motif may play 
a role in recruiting β-TrCP and subsequent degradation of the 
target protein. In total, the activity of Vpu to localize optimally in 
TGN and to colocalize with tetherin is parallel with the capability 
to down-modulate cell surface tetherin but not to enhance virion 
release. Colocalization of Vpu and tetherin may be sufficient to 
induce down-modulation of tetherin from cell surface but subse-
quent degradation of the restriction factor may also be required 
for efficient virion release.
On the other hand, it has been reported that Vpu retains newly 
synthesized CD4 in ER and targets it to proteasomal degradation 
(Lenburg and Landau, 1993; Bour et al., 1995; Paul and Jabbar, 
1997; Margottin et al., 1998; Magadán et al., 2010). Thus, we were 
interested in analyzing whether Vpu colocalizes with CD4 intrac-
ellularly. However, as mentioned earlier, Vpu did not localize the 
ER marker calreticulin in our assays. Furthermore, colocalization 
of Vpu and CD4 was not detected in MAGI cells transfected with 
a WT Vpu construct (data not shown). Evidently, it is necessary 
to examine more thoroughly the intracellular localization of Vpu 
and CD4.
dIscussIon
In this study we analyzed mutational effects on major Vpu activi-
ties as summarized in Table 1, and identified two functional clus-
ters within TMD and CTD required for efficient viral replication 
(Figure 1). Replication-defective vpu mutants were unable to pro-
mote virion release and also to down-modulate CD4 expression at 
the cell surface (V9D, I19D, S56G, and E59K) (Figures 2 and 4). 
Our results here indicate that these two Vpu functions are necessary 
for efficient viral replication, and that functional regions for virion 
release and CD4 down-modulation overlap each other.
Transmembrane domain mutants (V9D and I19D) were unable 
to down-modulate the cell surface tetherin (Figure 5) and to colo-
calize with tetherin extensively (Figure 7). These results were similar 
to those obtained using a randomized TMD mutants (Van Damme 
et al., 2008; Dubé et al., 2010). It is not clear that inability of the 
Using these FLAG-tagged Vpu constructs, we analyzed intracel-
lular localization of Vpu in HEp2 cells. Experiments for microscopic 
analysis were performed similarly with those for virion release 
assays to ensure direct functional comparison between the virion 
release and intracellular localization. As shown in Figure 7, WT 
Vpu localized in intracellular compartments stained with the TGN 
marker TGN46, and colocalized with tetherin in good agreement 
with the results reported previously (Dubé et al., 2009). None of WT 
and mutant Vpu proteins localized with the ER marker calreticulin, 
and their colocalization with the late endosome marker CD63 was 
rarely seen (data not shown). Mutants I24D and RK30AA, which 
have the ability to promote virion release and to down-modulate 
cell surface tetherin, were detected in the TGN46-positive compart-
ment and colocalized with tetherin like WT Vpu.
A Vpu TMD mutant I19D, defective for enhancing virion 
release and for inducing down-modulation of tetherin, showed 
altered localization and its expression was diffusely observed in the 
FIgure 6 | expression and activity of C-terminally FLAg-tagged Vpu 
constructs. (A) Western blot analysis of Vpu expression in lysates of 293T cells 
transfected with pSG-VpucFLAG vectors. Equivalent amounts of total protein 
(1 μg) were loaded and Vpu was detected by anti-FLAG antibody. β-Actin was 
used as a control. EV, empty vector control. (B) Virion release assays from 
HEp2 cells. HEp2 cells were transfected with the indicated proviral construct 
(300 ng) and pSG-VpucFLAG vectors (200 ng), and virion production in the 
culture supernatants on day 2 post-transfection was determined by RT assays. 
Values represent virion production level relative to that by WT proviral clone 
(NL4-3). Gray bar shows the results of proviral ∆Vpu (pNL-uE65). Black bar 
indicates the results of complementation of ∆Vpu (pNL-uE65) by WT Vpu 
(pSG-WT VpucFLAG). Blue and white bars show the results of expression 
vectors derived from replication-defective and replication-normal mutants in H9 
cells, respectively. EV, empty vector control pSG5 (400 ng).
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from cell surface, and to localize in TGN (Figures 4, 5, and 7), but 
showed a small defect in viral replication and trans-complemen-
tation assays (Figures 1E, 3B, and 6B). These observations would 
represent a subtle effect of the I24D mutation within TMD on 
TMD mutants to reduce cell surface tetherin is due to an indirect 
effect by their altered intracellular localization, a direct effect by 
their lack of binding to tetherin, or both. The I24D mutant had a 
similar ability with WT Vpu to down-modulate CD4 and tetherin 
FIgure 7 | Localization of Vpu to TgN and colocalization with tetherin. 
HEp2 cells were transfected with ∆Vpu (pNL-uE65) and the indicated vectors 
expressing FLAG-tagged Vpu (Figure 6). On the next day, cells were fixed, 
permeabilized, and immunostained with an anti-FLAG (red for Vpu), an 
anti-TGN46 (green), or an anti-HM1.24 (green for tetherin) antibody. Nuclei were 
counterstained with DAPI (blue). Cells were observed by confocal microscopy. 
Intracellular localization of each Vpu protein was analyzed for around 15 
Vpu-positive cells, and representative results were shown. Except for I19D, the 
colocalization of WT and mutant Vpu proteins with TGN46 and tetherin was 
observed in more than 80% cells examined. White bar, 10 μm.
Table 1 | Characteristics of HIV-1 vpu mutants.
Clones replication Virion release Down-regulation of Down-regulation Localization 
 kinetics enhancement surface tetherin of surface CD4 in cells
WT +++ 100.0 ++ ++ Localizes with TGN46 and tetherin
∆Vpu + 34.3 – – 
V9D ++ 49.0 + + Diffuse in cytoplasm
I19D + 38.0 −/+ – Diffuse in cytoplasm
I24D +++ 95.0 ++ ++ Similar to WT
RK30AA +++ 107.0 ++ ++ Similar to WT
S56G ++ 50.5 ++ – Similar to WT but more extensively 
     localizes with tetherin
E59K ++ 52.5 ++ – Similar to WT but more extensively 
     localizes with tetherin
M70V +++ 114.0 ++ ++ ND
WT, wild-type; ND, not determined.
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region for Vpu localization and virion release has been proposed 
(Ruiz et al., 2008). In this study, however, we did not observe any 
functional abnormality for the RK30AA mutant. The reason for this 
discrepancy is unclear but may be due to difference in cell type, viral 
strain, and method used in the individual experiment. In contrast to 
TMD mutants, CTD mutants (S56G and E59K) were able to down-
modulate cell surface tetherin without promoting virion release 
(Figures 2 and 5). This down-modulation of cell surface tetherin 
could be explained by its sequestration through extensive intrac-
ellular colocalization with the CTD mutants (Dubé et al., 2010). 
In addition, CTD mutants complemented virion release relatively 
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This could be due to the ability of CTD mutants to down-regulate 
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regulate the tetherin from cell surface (Figure 5). The defective 
nature of the CTD mutants suggests that recruitment of β-TrCP by 
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